IPP Bureau
EMA approves Biocon Biologics’ new mAbs facility in India
By IPP Bureau - June 24, 2024
Renews GMP certifications for India and Malaysia sites
CCRAS to organize national consultative meet on ‘Research Priority Settings in Traditional Medicine’ in collaboration with WHO
By IPP Bureau - June 24, 2024
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
.jpg "Cipla gets 6 observations from USFDA for Goa facility")
Cipla gets 6 observations from USFDA for Goa facility
By IPP Bureau - June 24, 2024
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Ami Organics raises Rs. 400 crores through QIP
By IPP Bureau - June 24, 2024
The Issue opened on June 18, 2024 and closed on June 21, 2024
AstraZeneca Pharma India updates on exploring contract manufacturer
By IPP Bureau - June 24, 2024
The company will now explore a buyer for its manufacturing site and exit in due course
Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer
By IPP Bureau - June 22, 2024
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
AbbVie appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors
By IPP Bureau - June 22, 2024
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Bristol Myers Squibb receives USFDA accelerated approval of Krazati in combination with Cetuximab for CRC
By IPP Bureau - June 22, 2024
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
By IPP Bureau - June 22, 2024
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Sumitomo Pharma presents new clinical data on DSP-5336 at the European Hematology Association 2024 Congress
By IPP Bureau - June 20, 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma aims global license agreement with Takeda for Olverembatinib
By IPP Bureau - June 20, 2024
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
Sensitech acquires Berlinger & Co. Monitoring Solutions to strengthen life sciences cold chain solutions
By IPP Bureau - June 20, 2024
Berlinger brings a suite of proprietary and high-quality hardware and software solutions that broaden Sensitech's end-to-end cold chain monitoring product portfolio
Roche receives FDA clearance on its digital pathology solution for diagnostic use
By IPP Bureau - June 20, 2024
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
By IPP Bureau - June 19, 2024
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Cipla EU to invest an additional € 3 million in Ethris
By IPP Bureau - June 19, 2024
Cipla had earlier invested € 15 million in Ethris in 2022
